欧洲精品一区二区三区_欧美性性性性_国产一区二区免费在线播放_日日噜噜噜噜人人爽日本精品_无套中出丰满人妻无码_国产偷窥熟女精品视频大全

加拿大Resverlogix  
Resverlogix Corp. (TSX: RVX) 是一家心血管疾病臨床研究公司，公司擁有能夠調節蛋白質形成的表觀遺傳學平臺技術。Resverlogix 正在開發 RVX-208——用于治療動脈粥樣硬化的同類首個小分子。RVX-208 是首個正在進行臨床試驗的 BET 溴區結構域抑制劑。出自 Resverlogix 表觀遺傳學藥物發現平臺的新復合制劑通過抑制 BET 溴區結構域而發揮作用，并有希望用來治療癌癥、自身免疫性疾病和神經退行性疾病等多種病癥。Resverlogix 的普通股在多倫多證券交易所交易 (TSX: RVX)。

Resverlogix Corp. is a publicly traded biotechnology company (TSX:RVX) engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas? Plaque Regression program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I production. These vital therapies are focused to address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Alzheimer's disease, Peripheral Artery Disease and Autoimmune diseases.

Our Business Model is to seek strategic opportunities through early alliance partnerships that are best suited to bring our technology platforms to successful commercialization. We are committed to good corporate governance and protection of shareholder value.